JP2021521171A5 - - Google Patents
Info
- Publication number
- JP2021521171A5 JP2021521171A5 JP2020555466A JP2020555466A JP2021521171A5 JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5 JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2021521171 A5 JP2021521171 A5 JP 2021521171A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sugar
- preparation according
- item
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521171A JP2021521171A (ja) | 2021-08-26 |
| JP2021521171A5 true JP2021521171A5 (enExample) | 2022-04-15 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555466A Pending JP2021521171A (ja) | 2018-04-10 | 2019-04-10 | 治療用抗体の安定な製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (enExample) |
| EP (1) | EP3773696A4 (enExample) |
| JP (1) | JP2021521171A (enExample) |
| CN (1) | CN112292146A (enExample) |
| AU (1) | AU2019251453A1 (enExample) |
| BR (1) | BR112020020703A2 (enExample) |
| CO (1) | CO2020013571A2 (enExample) |
| SG (1) | SG11202009876TA (enExample) |
| WO (1) | WO2019198101A1 (enExample) |
| ZA (1) | ZA202006264B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10994011B2 (en) | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
| US20250092141A1 (en) * | 2021-12-27 | 2025-03-20 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4615502A1 (en) | 2022-11-07 | 2025-09-17 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| CA2690382A1 (en) * | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| WO2009080541A1 (en) * | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20210322549A1 (en) | 2015-07-17 | 2021-10-21 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Natalizumab |
| CA3143167A1 (en) | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Methods of producing an anti-.alpha.4.beta.7 antibody |
-
2019
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024001364A5 (enExample) | ||
| JP2021521159A5 (enExample) | ||
| EP3041504B1 (en) | Thermally stable vaccine formulations and microneedles | |
| JP2019536761A5 (enExample) | ||
| JP2021503485A5 (enExample) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| HRP20251316T1 (hr) | Stabilne formulacije polipeptida i njihova upotreba | |
| JP2017516848A5 (enExample) | ||
| JP2012515221A5 (enExample) | ||
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| JP2014139229A5 (enExample) | ||
| RU2016150640A (ru) | Жидкая фармацевтическая композиция | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| JP2013521296A5 (enExample) | ||
| CN101631563B (zh) | 含有流感疫苗的冻干制剂及其制备方法 | |
| JP2019504086A5 (enExample) | ||
| HRP20250830T1 (hr) | Farmaceutski pripravak s niskim ph koji sadrži konstrukte protutijela koja djeluju na t-stanice | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| JP2017516847A5 (enExample) | ||
| RU2013148119A (ru) | Лиофилизированный препарат ботулотоксина | |
| FI2608805T4 (fi) | NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| JP2015535237A5 (enExample) | ||
| JP2018531578A5 (enExample) |